• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Molecular Templates Inc.

    11/15/24 6:05:26 AM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTEM alert in real time by email
    NT 10-Q 1 d855154dnt10q.htm NT 10-Q NT 10-Q

    SEC FILE NUMBER

    001- 32979

    CUSIP NUMBER

    608550 208

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 12b-25

     

     

    NOTIFICATION OF LATE FILING

     

    (Check One):   

    ☐ Form 10-K  ☐ Form 20-F  ☐ Form 11-K  ☒ Form 10-Q

    ☐ Form 10-D  ☐ Form N-CEN  ☐ Form N-CSR

      For Period Ended: September 30, 2024
      ☐ Transition Report on Form 10-K
      ☐ Transition Report on Form 20-F
      ☐ Transition Report on Form 11-K
      ☐ Transition Report on Form 10-Q
      For the Transition Period Ended:  

     

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

       

     

    PART I - REGISTRANT INFORMATION

    Molecular Templates, Inc.

    Full Name of Registrant

    N/A

    Former Name if Applicable

    9301 Amberglen Blvd, Suite 100

    Address of Principal Executive Office (Street and Number)

    Austin, Texas 78729

    City, State and Zip Code

    PART II - RULES 12b-25(b) AND (c)

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

    ☐     (a)   The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
      (b)   The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
      (c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

    PART III - NARRATIVE

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

    Molecular Templates, Inc. (the “Company”) is filing this Notification of Late Filing on Form 12b-25 with respect to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (“Form 10-Q”). The Company is unable to file, without unreasonable effort or expense, its Form 10-Q within the prescribed time period due to the related costs and resources required to complete and review the financial statements to be included in such Form 10-Q. At this time, the Company cannot estimate when or if it will be able to file its Form 10-Q.

    PART IV - OTHER INFORMATION

     

    (1)       Name and telephone number of person to contact in regard to this notification.
        Eric E. Poma       512       869-1555
        (Name)     (Area Code)     (Telephone Number)
    (2)     Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐
         
    (3)     Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ☒ No ☐
        If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
        The Company’s results of operations for the quarter ended September 30, 2024 may differ significantly from its results of operations for the quarter ended September 30, 2023 due to adverse developments that occurred with respect to the Company’s business and liquidity, including events in connection with the Company’s previously disclosed potential liquidation and dissolution. Due to the exploration of strategic alternatives, including the Company’s previously disclosed potential liquidation and dissolution, the Company is not able to provide an estimate of results of operations at this time.
        Forward-Looking Statements
        This Form 12b-25 includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements contained in this Form 12b-25 include, but are not limited to, statements regarding the Company’s ability to file its Form 10-Q and the Company’s estimates of results of operations. These statements are based on management’s current expectations, and actual results and future events may differ materially due to risks and uncertainties, including, without limitation, risks inherent in the potential liquidation and dissolution process; the Company’s financial projections and cost estimates; the Company’s ability to raise additional funds during the potential liquidation and dissolution process; and the effect of the potential liquidation and dissolution on the Company’s business prospects, financial results and business operations. The Company may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on its forward-looking statements. These and other factors that may affect the Company’s future business prospects, results and operations are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s most recent Annual Report filed on Form 10-K and the subsequently filed Quarterly Reports on Form 10-Q. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this Form 12b-25. Except as required by applicable law, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

     

     

    Molecular Templates, Inc.

    (Name of Registrant as Specified in Charter)

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date:  November 15, 2024   By:   /s/ Eric E. Poma, Ph.D.
        Name:   Eric E. Poma, Ph.D.
        Title:   Chief Executive Officer

     

     

     

    Get the next $MTEM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTEM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTEM
    SEC Filings

    See more
    • SEC Form 8-K filed by Molecular Templates Inc.

      8-K - Molecular Templates, Inc. (0001183765) (Filer)

      1/2/25 4:13:52 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Molecular Templates Inc.

      8-K - Molecular Templates, Inc. (0001183765) (Filer)

      12/19/24 4:11:29 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Molecular Templates Inc.

      DEFA14A - Molecular Templates, Inc. (0001183765) (Filer)

      12/4/24 4:10:56 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTEM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

      SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. "We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepa

      4/23/25 8:00:00 AM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules

      AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM" or the "Company")), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, was notified on December 16, 2024 by the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") of the Staff's determination pursuant to Nasdaq Listing Rule 5101 that the Company is a "public shell," and that, in the view of the Staff, the continued listing of the

      12/19/24 4:10:00 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements

      AUSTIN, Texas, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM" or the "Company")), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, announced that it has received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on November 25, 2024. The notice indicated that MTEM is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") as a result of

      12/2/24 5:06:43 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTEM
    Leadership Updates

    Live Leadership Updates

    See more
    • Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

      SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. "We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepa

      4/23/25 8:00:00 AM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer

      AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced the appointment of Dr. Maurizio Voi to the role of Chief Medical Officer. Dr. Voi possesses more than 35 years of wide-ranging drug development experience. Dr. Voi will begin his new role on October 2, 2023. Dr. Voi joins MTEM from Novartis, where he served as Vice President, Global Program Head, for the PD-1 antibody Tislelizumab since April 2021. He was previously Global Program Head, Melanoma, at Novartis, a pos

      9/28/23 4:11:00 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Molecular Templates Strengthens Board of Directors and Management Team

      Industry Veteran Gabriela Gruia, M.D., appointed to Board of Directors Megan Filoon promoted to General Counsel AUSTIN, Texas, March 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM" or "the Company"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced the appointment of Gabriela Gruia, M.D., to its Board of Directors and the promotion of Megan Filoon to General Counsel. "Dr. Gruia brings a wealth of industry knowledge to our Board of Directors," said Barry Selick, Ph.D., Chairman of the Board of Molecular

      3/2/22 8:00:00 AM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities initiated coverage on Molecular Templates with a new price target

      BofA Securities initiated coverage of Molecular Templates with a rating of Buy and set a new price target of $12.00

      4/21/21 6:52:47 AM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Molecular Templates with a new price target

      UBS initiated coverage of Molecular Templates with a rating of Neutral and set a new price target of $13.00

      2/1/21 7:51:02 AM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

      SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

      11/18/24 9:49:56 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

      SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

      11/14/24 4:37:56 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

      SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

      11/12/24 9:31:46 AM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Biotech Target N V sold $845,833 worth of shares (1,279,820 units at $0.66), closing all direct ownership in the company (SEC Form 4)

      4 - Molecular Templates, Inc. (0001183765) (Issuer)

      11/18/24 9:12:24 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lalande Kevin M.

      4 - Molecular Templates, Inc. (0001183765) (Issuer)

      9/30/24 5:41:36 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Gruia Gabriela

      4 - Molecular Templates, Inc. (0001183765) (Issuer)

      9/30/24 5:37:40 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Biotech Target N V bought $587,500 worth of shares (250,000 units at $2.35), increasing direct ownership by 24% to 1,279,820 units (SEC Form 4)

      4 - Molecular Templates, Inc. (0001183765) (Issuer)

      4/4/24 8:13:35 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care